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occurred.Pearson correlation and linear regression showed higher correlation with ECT
than ACT to bivalirudin concentration (r0.859 versus 0.824, p0.001; r-sq 0.73 versus
0.68, p0.24).
Conclusions: Helena Laboratories Point-of-care DTM assay has higher correlation with
bivalirudin concentration across a wide range of doses com.ECT monitoring of bivaliru-
din may help reduce both thrombotic and bleeding complications in patients undergoing
PCI.
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Background: Percutaneous coronary intervention (PCI) with rotational atherectomy
(RA) is associated with a high incidence of peri-procedural myocardial infarction (MI)
and local vascular complications. While bivalirudin has emerged as an attractive
alternative to heparin in patients undergoing contemporary PCI, it is unclear if such a
strategy has advantages in patients undergoing RA.
Methods: ROTAXUS randomly assigned 240 patients with calcified coronary lesions to
RA followed by stenting (n120) or stenting without RA (n120, standard therapy
group). Stenting was performed using a polymer-based paclitaxel-eluting stent. Proce-
dural anticoagulation therapy was determined by the treating physician. For the current
analysis, patients receiving bivalirudin (n129) were compared to those receiving
unfractionated heparin (UFH, n111) during PCI. Efficacy was assessed by the frequency
of peri-procedural MI according to the universal MI definition (Troponin T elevation 3
times the 99th percentile URL). Safety was assessed by the frequency of major access site
bleeding (ASB) according to the ACUITY trial definition.
Results: Baseline characteristics were similar in the bivalirudin and UFH groups. All
patients were preloaded with aspirin and clopidogrel. Glycoprotein IIb/IIIa inhibitors were
used in 1 patient in the bivalirudin group and 3 patients in the UFH group (p0.24).
Peri-procedural MI occurred less frequently in the bivalirudin compared to the UFH group
(22% vs. 37.5%, p0.02), while ASB was similar (2.3% vs. 5.5%, p0.20). There was
an interaction between the use of RA and bivalirudin regarding both efficacy and safety
endpoints. In the RA group, bivalirudin significantly reduced the incidence of peri-
procedural MI (15.7% vs. 38.7%, p0.01) with a strong trend towards reduced major
ASB (2.9 vs. 10.2%, p0.09) compared with UFH. In the standard therapy group,
bivalirudin was similar to UFH regarding peri-procedural MI (28.6% vs. 36.6%, p0.42)
and major ASB (1.7 vs. 1.7%, p1.0).
Conclusions: This analysis suggests the existence of an interaction between PCI with RA
and bivalirudin therapy, with significantly less peri-procedural MI and fewer access-site
complications with bivalirudin compared to UFH.
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Background: Pulmonary thromboendarterectomy has been a definitive option for central
type of Chronic Thromboembolic Pulmonary Hypertension (CTEPH). However, patients
with thromboembolism in the peripheral segments have shown poor prognosis, because
such lesions are surgically inaccessible. Therefore, we performed an innovative new
approach of balloon pulmonary angioplasty (BPA) for inoperable CTEPH cases and
evaluated the efficacy and safety of this treatment.
Methods: We performed 34 sessions of BPA for 11 patients who suffered from
inoperable peripheral type of CTEPH with mean pulmonary artery pressure (mPAP) 
25mmHg and WHO functional class (WHO-Fc) III or IV in spite of under medical
therapy with Bosentan, Sildenafil, or Tadarafil. We evaluated hemodynamic parameters
by Swan-Ganz catheter pre oral medical therapy, pre and post BPA. BPA was repeated
in 16 sessions to every patient depending on their severity.
Results: Medical treatment performed before BPA did not improve hemodynamic
parameters (Table). However, BPA dramatically improved hemodynamic parameters
such as a significant increase in Cardiac output (CO) and decrease in mPAP and
pulmonary vascular resistance (PVR), which are accompanied with improved 6 minutes
walk distance and WHO-Fc after BPA therapy. On the other hand, reperfusion pulmonary
injury occurred in 18 sessions after BPA with 2 sessions required emergent intubation due
to hemorrhagic pulmonary edema. There were no mortal complications.
Pre medical
treatment Pre BPA Post BPA P value
CO
(L/min)
3.771.11 3.690.91 5.461.24 0.0027
mPAP
(mmHg)
37.27.7 38.37.7 20.93.7 0.0001
PVR
(dyne/cm5)
731.0351.6 693.8363.2 235.1137.4 0.0008
6MWD (m) 307.18.2 272.496.9 486.073.3 0.0122
WHO Fc 3.270.47 3.090.54 1.450.52 0.0001
Conclusions: BPA could be an effective treatment option for inoperable peripheral type
CTEPH to achieve dramatic improvement of hemodynamic and outcome parameters.
Further technical modification in attempting to reduce procedural complications will be
required.
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Background: Recently the efficacy of the Balloon Pulmonary Angioplasty (BPA) for
Chronic thromboembolic pulmonary hypertension (CTEPH) have been reported. The
objective of this study was to reveal the late response of pulmonary artery diameter and
hemodynamics after BPA.
Methods: BPA was successfully performed for 9 CTEPH patients (23 sessions, average
2.61.0 sessions per patient). Quantitative Angiography (QA) and right heart catheter-
ization were performed pre, post and at chronic phase (112.448.2 days) after BPA.
Results: Immediately after BPA, mean pulmonary arterial pressure (mPAP) and
pulmonary vascular resistance (PVR) showed slight decrease, followed by significant
drop at chronic phase after BPA. QA revealed that minimal lumen diameter at ballooning
site (MLD-b) and 10 mm distal segment to balloon inflation site (MLD-d) significantly
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